ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Sunday, November 12, 2023

11:00AM-12:30PM: Abstract Number: 0726

Expert Consensus Recommendations for Musculoskeletal Ultrasound Education in Canadian Rheumatology Residency Training Programs

Plenary I

11:00AM-12:30PM: Abstract Number: 0723

Investigating the Effects and Molecular Mechanisms of TRAF5 on the Pathogenesis of SLE Associated Pulmonary Arterial Hypertension

Plenary I

11:00AM-12:30PM: Abstract Number: 0725

Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis

Plenary I

11:00AM-12:30PM: Abstract Number: 0724

Synovial Macrophage Subsets Defined by ScRNAseq Demonstrate Sexually Dimorphic Gene Expression in RA and a Mouse Inflammatory Arthritis Model

Plenary I

2:00PM-3:30PM: Abstract Number: 0738

A Genome-wide Association Study Suggests New Susceptibility Loci for Primary Antiphospholipid Syndrome

Abstracts: Genetics, Genomics & Proteomics

2:00PM-3:30PM: Abstract Number: 0771

A Modified Idiopathic Pulmonary Fibrosis-Derived Composite Biomarker Score Is Associated with Interstitial Lung Disease Among U.S. Veterans with Rheumatoid Arthritis

Abstracts: RA – Diagnosis, Manifestations, & Outcomes I: RA-ILD

2:00PM-3:30PM: Abstract Number: 0727

A Novel Active Pemphigus Vulgaris Mouse Model Induced by Immunization with TLR Ligand Adjuvanted Recombinant Desmoglein 3 Protein Vaccine

Abstracts: B Cell Biology & Targets in Autoimmune & Inflammatory Disease

2:00PM-3:30PM: Abstract Number: 0786

A Retrospective Analysis of the Efficacy of the Euro-Lupus Nephritis Cyclophosphamide Regimen versus NIH Regimen in a South Carolina Lupus Nephritis Cohort

Abstracts: SLE – Treatment I: Renal

2:00PM-3:30PM: Abstract Number: 0741

Adverse Events Among Patients with and Without Autoimmune Rheumatic Disease Prescribed SGLT2 Inhibitors

Abstracts: Epidemiology & Public Health I

2:00PM-3:30PM: Abstract Number: 0764

An Atypical ClassRheum: RheumMadness, a Collaborative Rheumatology Competition Building Knowledge and Community

Abstracts: Professional Education

2:00PM-3:30PM: Abstract Number: 0745

Artificial Intelligence Models for Computer-Assisted Joint Detection and Sharp-van Der Heijde Score Prediction in Hand Radiographs from Patients with Rheumatoid Arthritis

Abstracts: Imaging of Rheumatic Diseases

2:00PM-3:30PM: Abstract Number: 0780

Assessing Differential Effects of DMARDs on Psoriasis Area and Severity Index and Patient Global Assessment in Subgroups of Patients with Active PsA Treated over 52-weeks with Secukinumab in a Non-Interventional Trial (AQUILA) Using a Multistage Clustering Approach

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment I: PsA

2:00PM-3:30PM: Abstract Number: 0748

Assessment of Myositis-related Interstitial Lung Disease by ⁶⁸ Ga-DATA.SA.FAPi PET/CT

Abstracts: Imaging of Rheumatic Diseases

2:00PM-3:30PM: Abstract Number: 0755

Changes in Rheumatology Providers’ Perceptions of Telehealth Appropriateness from 2021 to 2022

Abstracts: Measures & Measurement of Healthcare Quality

2:00PM-3:30PM: Abstract Number: 0777

Characteristics of Difficult-To-Treat Psoriatic Arthritis: A Comparative Analysis

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment I: PsA

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].